- Previous Close
5.3900 - Open
5.3500 - Bid --
- Ask --
- Day's Range
4.9250 - 5.3700 - 52 Week Range
4.9250 - 15.4200 - Volume
70,419 - Avg. Volume
62,066 - Market Cap (intraday)
341.827M - Beta (5Y Monthly) 1.56
- PE Ratio (TTM)
-- - EPS (TTM)
-2.8000 - Earnings Date Jun 2, 2025
- Forward Dividend & Yield --
- Ex-Dividend Date --
- 1y Target Est
25.42
ABIVAX Société Anonyme, a clinical-stage biotechnology company, focuses on developing therapeutics that harness the body's natural regulatory mechanisms to stablize the immune response in patients with chronic inflammatory diseases. The company is evaluating its lead drug candidate, obefazimod, in Phase 3 clinical trials for the treatment of moderately to severely active ulcerative colitis in adults. ABIVAX Société Anonyme was incorporated in 2013 and is headquartered in Paris, France.
www.abivax.comRecent News: ABVX.PA
View MorePerformance Overview: ABVX.PA
Trailing total returns as of 4/4/2025, which may include dividends or other distributions. Benchmark is CAC 40 (^FCHI) .
YTD Return
1-Year Return
3-Year Return
5-Year Return
Compare To: ABVX.PA
Select to analyze similar companies using key performance metrics; select up to 4 stocks.
Statistics: ABVX.PA
View MoreValuation Measures
Market Cap
317.09M
Enterprise Value
270.23M
Trailing P/E
--
Forward P/E
--
PEG Ratio (5yr expected)
--
Price/Sales (ttm)
--
Price/Book (mrq)
7.81
Enterprise Value/Revenue
--
Enterprise Value/EBITDA
--
Financial Highlights
Profitability and Income Statement
Profit Margin
0.00%
Return on Assets (ttm)
-40.62%
Return on Equity (ttm)
-148.98%
Revenue (ttm)
10.79M
Net Income Avi to Common (ttm)
-176.24M
Diluted EPS (ttm)
-2.8000
Balance Sheet and Cash Flow
Total Cash (mrq)
144.36M
Total Debt/Equity (mrq)
269.12%
Levered Free Cash Flow (ttm)
-102.37M